Research Paper Volume 15, Issue 19 pp 10453—10472
An immune signature to predict the prognosis of ATRX-wildtype glioma patients and guide immune checkpoint blockade therapy
Figure 4. Key genes selected for risk model construction. (A, B) LASSO analysis of key genes associated with survival in ATRX-wt glioma patients. (C) Multivariate Cox regression analysis of HOXA5, PTPN2, WT1, HOXD10, POSTN, ADAMDEC1 and MYBPH. These seven genes were used for risk model construction.